DRUG
A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity
Status
Terminated
Phase
Phase 2
Enrollment
120
Locations
0
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
This is a multicenter, randomized, placebo-controlled, double-blind, Phase 2 study. Patients will be treated for a total of 12 weeks. There will be a 6 week follow-up period after the treatment period ends. Patients will be randomly assigned to low dose CJC 1295, high dose CJC 1295 or placebo. The objective is to assess and compare the efficacy, pharmacokinetics, safety, and tolerability of CJC 1295 in patients with human immunodeficiency virus (HIV) associated visceral obesity.
Interventions
Treatment arms and agents.
Timeline
From registration to results.
First posted
Dec 21, 2005
Study start
Dec 2005
Primary completion
Not reported
Study completion
Sep 2006
Results posted
Not reported
Registry updated
Oct 16, 2006
Outcomes
What the study measures.
Primary outcomes
Not reported in the indexed record.
Secondary outcomes
Not reported in the indexed record.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 65 Years
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Age 18-65 on stable antiviral regimen * Documented HIV infection * HIV associated visceral obesity * Body mass index (BMI) \> 24 and \< 30 kg/m2 Exclusion Criteria: * Diabetes * Use of growth hormone (GH) or other GH secretagogues * Use of systemic glucocorticoids, * Use of megestrol acetate or other appetite stimulants, * Use of general anorexigenic or weight-reducing agents, or * Use of androgens, other than testosterone replacement therapy for male hypogonadism at physiological doses and on a stable regimen for at least 6 months prior to randomization.
Study locations
0 registered sites.
No country data reported. Showing up to 24 locations stored in the fast local snapshot.
No study locations reported.
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on CJC-1295.
No studies in this snapshot.
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.